Semaglutide versus sitagliptin after liver transplant for diabetes
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial compares two diabetes medicines—semaglutide and sitagliptin—in people who have had a liver transplant and have type 2 diabetes (or diabetes after transplant). It’s looking to see which medicine works better and is safe for blood sugar control in the transplant setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and able to give informed consent.
- You received a liver transplant (liver or kidney-liver transplants and repeat transplants are allowed), and it’s been at least 3 months since surgery.
- There is no current active rejection, and your liver blood tests are stable (or high because of fatty liver disease confirmed on biopsy).
- You have type 2 diabetes or post-transplant diabetes, and your HbA1c is between 6.5% and 10.5%.
- Your current diabetes medicines are limited to what the trial allows (metformin and/or an SGLT2 inhibitor are allowed if stable; insulin is allowed if it’s been stable for at least 90 days).
- You do not have certain exclusions like recent heart attack/stroke, very low kidney function (eGFR under 30), recent investigational drugs, pancreas inflammation history, or certain thyroid cancer/MEN2 history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
This study tests whether a weight loss medication (semaglutide) can help manage obesity in people who have had a kidney transplant or are at high risk. It aims to improve health outcomes and prevent further kidney decline.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.